Literature DB >> 22392422

Prescription ergocalciferol dosing for vitamin D repletion: a retrospective evaluation.

Joseph P Vande Griend1, Robert B McQueen, Sunny A Linnebur, Sheryl F Vondracek.   

Abstract

STUDY
OBJECTIVES: To determine the efficacy and safety of vitamin D repletion with prescription ergocalciferol and to determine patient-specific factors that may influence the amount of ergocalciferol needed to attain vitamin D sufficiency.
DESIGN: Retrospective medical record review.
SETTING: University-affiliated outpatient health system. PATIENTS: A total of 1446 patients aged 18-89 years who had a prescription for ergocalciferol 50,000 IU between January 1, 2007, and December 31, 2008, were identified; of these patients, 582 patients had a vitamin D concentration measured 120 days before their first prescription (baseline) and had another concentration measured 60-180 days after this prescription (follow-up) and were deemed "first-time users" of ergocalciferol.
MEASUREMENTS AND MAIN RESULTS: Vitamin D sufficiency was defined as a 25-hydroxyvitamin D (vitamin D) concentration of 30 ng/ml or higher. Twenty-nine different ergocalciferol prescribing regimens were identified in the 1446 patients. For the 582 first-time users of ergocalciferol, vitamin D concentrations increased from a mean ± SE of 17.7 ± 0.32 ng/ml at baseline to 32.9 ± 0.73 ng/ml at first follow-up concentration, with a mean ± SE prescribed ergocalciferol dose of 63,876 ± 1973 IU given over an average of 17 weeks. Overall, 326 (56%) of the 582 first-time users attained sufficiency with their prescribed regimen. With use of a logistic regression model to control for variables that could influence a patient's response to vitamin D, patients prescribed 50,000-100,000 IU/week were significantly more likely to attain vitamin D sufficiency compared with those prescribed less than 50,000 IU/week (OR 2.61, 95% CI 1.37-4.99). Body mass index of 30 kg/m(2) or higher decreased the odds of attaining vitamin D sufficiency, whereas use of a loading dose did not increase the odds of attaining sufficiency.
CONCLUSION: Many different ergocalciferol regimens were used to replace vitamin D, and overall attainment of vitamin D sufficiency appeared to be moderate. Based on our findings, an ergocalciferol regimen of 50,000-100,000 IU/week with no loading dose could be considered as a starting point for vitamin D repletion.
© 2012 Pharmacotherapy Publications, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392422     DOI: 10.1002/PHAR.1052

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Response of Vitamin D Concentration to Vitamin D3 Administration in Older Adults without Sun Exposure: A Randomized Double-Blind Trial.

Authors:  Janice B Schwartz; Lynn Kane; Daniel Bikle
Journal:  J Am Geriatr Soc       Date:  2016-01       Impact factor: 5.562

Review 2.  Factors Affecting 25-Hydroxyvitamin D Concentration in Response to Vitamin D Supplementation.

Authors:  Hajar Mazahery; Pamela R von Hurst
Journal:  Nutrients       Date:  2015-06-25       Impact factor: 5.717

3.  Circulating 25-Hydroxy Vitamin D Relative to Vitamin D Receptor Polymorphism after Vitamin D3 Supplementation in Breast Cancer Women: A Randomized, Double-Blind Controlled Clinical Trial

Authors:  Houra Mohseni; Seyed Ahmad Hosseini; Reza Amani; Alireza Ekrami; Ahmad Ahmadzadeh; Seyed Mahmoud Latifi
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

4.  Effects of a 10-day course of a high dose calciferol versus a single mega dose of ergocalciferol in correcting vitamin D deficiency.

Authors:  Samar Jamal Melhem; Khaled Mohammad Aiedeh; Kamal Abdelhamid Hadidi
Journal:  Ann Saudi Med       Date:  2015 Jan-Feb       Impact factor: 1.526

5.  Vitamin D resistance in chronic kidney disease (CKD).

Authors:  Amay Parikh; Herbert S Chase; Linda Vernocchi; Leonard Stern
Journal:  BMC Nephrol       Date:  2014-03-19       Impact factor: 2.388

6.  Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis.

Authors:  Yoon Sok Chung; Dong Jin Chung; Moo Il Kang; In Ju Kim; Jung Min Koh; Yong Ki Min; Han Jin Oh; Il Hyung Park; Yil Seob Lee; Barbara Kravitz; Brian Waterhouse; Lorraine A Fitzpatrick; Antonio Nino
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.